Replication licensing and the DNA damage checkpoint by Cook, Jeanette Gowen
Replication licensing and the DNA damage checkpoint
Jeanette Gowen Cook
Department of Biochemistry & Biophysics and Department of Pharmacology, Lineberger
Comprehensive Cancer Center, Campus Box 7260, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599
Abstract
Accurate and timely duplication of chromosomal DNA requires that replication be coordinated
with processes that ensure genome integrity. Significant advances in determining how the earliest
steps in DNA replication are affected by DNA damage have highlighted some of the mechanisms
to establish that coordination. Recent insights have expanded the relationship between the ATM
and ATR-dependent checkpoint pathways and the proteins that bind and function at replication
origins. These findings suggest that checkpoints and replication are more intimately associated
than previously appreciated, even in the absence of exogenous DNA damage. This review
summarizes some of these developments.
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2. INTRODUCTION
Normal cell cycle progression requires that the steps of DNA replication and segregation
occur in the proper space and time. Cell cycle checkpoints ensure that individual events,
such as replication initiation or mitotic entry, only occur under circumstances where the
intracellular and extracellular environments are compatible with successful cell division.
Failure to properly signal information about these environments puts cells at risk of lethal
damage or of generating daughter cells that carry harmful mutations or chromosomal
abnormalities. For this reason it is not surprising that checkpoint defects lead to genome
instability, which in turn, increases the likelihood of carcinogenesis.
The checkpoint system to detect and respond to DNA damage has traditionally been studied
in cells treated with exogenous genotoxic insults. However, recent molecular genetic
investigations of cell cycle checkpoint factors have shown that replication factors and
checkpoint signaling molecules are much more intimately associated than previously
appreciated. In particular, two signaling kinases, ATR and Chk1, are required for cell
viability even in the absence of exogenous DNA damage, and these two kinases influence
replication initiation and S phase progression in unperturbed cells. The earliest studies
implicated ATR and Chk1 in general cell cycle progression through control of Cdk
activation. However, additional findings suggest that ATR and Chk1 influence DNA
replication at other steps as well. There are a number of excellent reviews on the individual
subjects of DNA replication control (1–6) or the activation of the DNA damage checkpoint
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pathways (7–11). This review will focus primarily on the interaction of the ATR-Chk1
pathway with the regulation of the events that take place at replication origins.
3. DNA REPLICATION
3.1. Once and only once
Human cells face an enormous challenge as they initiate S phase. They must access and
duplicate more than 3 billion base pairs of DNA within a matter of hours. In order to
efficiently duplicate so much DNA, replication initiates at thousands of sites throughout the
genome. These replication origins do not initiate (“fire”) synchronously; instead they fire at
various times throughout S phase. Asynchronous origin firing sets up a second challenge:
how to prevent any origin from firing a second time within the same cell cycle. This task
seems daunting since origins that fire early in S phase exist in an environment containing
high levels of all of the necessary enzymes and substrates to support the assembly of a new
replication fork. Cells must simultaneously block rereplication from thousands of origins
that have already fired while permitting efficient firing of thousands of origins that have not
yet fired. Successfully accomplishing that task allows each chromosome to be fully
replicated exactly once per cell cycle.
In order to prevent rereplication, eukaryotic cells compartmentalize the steps of replication
into different cell cycle phases. First the origin is prepared for replication by the assembly of
a chromatin-bound multiprotein complex, the prereplication complex or preRC. Once this
complex has formed that origin is said to be “licensed” for replication, and licensing is only
permitted during G1 (Figure 1). Secondly, in S phase DNA synthesis initiates from the
licensed origins as a consequence of protein kinase activity from both Cdc7/Dbf4 and cyclin
E/Cdk2 which are activated at the G1/S transition. Once S phase has begun, multiple
overlapping mechanisms (discussed below) block the assembly of any new preRCs until
after chromosomes have segregated.
Experimental manipulations that perturb preRC control can result in substantial rereplication
and genome instability. The fact that normal cell have stable genomes leads to the
assumption that rereplication doesn’t normally occur. Nevertheless, many thousands of
potential sites for rereplication are present in each human cell, and it is not known if
rereplication is perfectly blocked or if perhaps a few origins re-fire each cell cycle. If limited
rereplication takes place even in normal cells, how do cells deal with the extra DNA? Are
some cell types more prone to rereplication than others? Might such rereplication be a
source of endogenous mutagenesis? The genome instability that is a hallmark of cancer cells
could partially reflect failure to maintain once per cell cycle replication, although a rigorous
examination of this aspect of genome stability in cancer cells has not yet been undertaken. A
thorough understanding of the ways in which licensing is controlled under a variety of
circumstances will shed light on such questions.
3.2. Origin licensing by preRC assembly
The preRC assembles in G1 in a step-wise fashion (reviewed in (5, 12, 13). The first step is
the binding of the Origin Recognition Complex (ORC) to the origin. ORC is a
heterohexamer composed of subunits Orc1–Orc6, and the complex has DNA-dependent
ATPase activity. ORC association with origins promotes the subsequent association of both
the Cdc6 ATPase and the Cdt1 protein. Cdt1 and Cdc6 are then responsible in cooperation
with ORC for the recruitment and loading of the Minichromosome Maintenance complex
(MCM). The loading of MCMs at origins is what distinguishes licensed from unlicensed
origins. The MCM complex consists of six polypeptides, Mcm2–Mcm7, and the MCM
complex is the current best candidate for the DNA helicase at replication forks. Consistent
with this model, MCM subunits, but not other preRC proteins, have been shown to travel
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with the replication fork (14). Multiple MCM complexes are loaded at each origin (15), and
the enzymatic activity of both Cdc6 and ORC are required to fully load each origin with its
complement of MCM (16). Assays of preRCs assembled in vitro indicate that once MCMs
are loaded, they no longer require ORC, Cdc6, or Cdt1 to remain functionally associated
with origins (17, 18). Ultimately however, the MCM complex is released from chromatin by
an as yet undetermined mechanism as the cell completes S phase (19, 20).
All origins that will be licensed in a given cell cycle – regardless of whether they will fire in
early or late S phase - receive MCM in G1. The MCM complexes that are loaded at origins
are tightly associated with chromatin, but are inactive throughout G1. The purified MCM
complex has weak, if any, DNA helicase activity, but DNA helicase activity is stimulated
when MCM associates with the Cdc45 protein and the GINS heterotetrameric complex
(consisting of Sld5, Psf1, Psf2, and Psf3) (21–25). Consistent with its function as an MCM
activator, Cdc45 does not arrive at any individual origin until just before or during the actual
initiation; thus Cdc45 is found at early-firing origins in early S phase and at late-firing
origins in late S phase (14).
The loading of GINS and Cdc45 to activate MCM and allow the establishment of a
productive replication fork requires the activity of the Cdc7/Dbf4 protein kinase and cyclin
E/Cdk2 activity. Cdc7 phosphorylates MCM to promote Cdc45 binding, and Cdk2 activity
stimulates the loading of the GINS complex, which in turn, is required for stable association
between Cdc45 and MCM (22). While it is clear that phosphorylation by both Cdc7/Dbf4
and cyclin E/Cdk2 are required for the association of these replication fork proteins at
origins, precisely how replication initiates is incompletely understood. Two recent studies of
yeast replication initiation defined phosphorylation of the Sld2 and Sld3 proteins as the
minimal Cdk-dependent phosphorylation events for S phase entry. These phosphorylations
are required for recruitment of Cdc45 to origins (26, 27). Sld3 has no clear ortholog in
metazoan genomes, so the search for an analogous factor to fill that role in human cells is an
important goal.
3.3. Restricting origin licensing to G1
Multiple mechanisms act after the G1/S transition to block licensing in order to prevent
rereplication. In theory, robust inhibition of just one component of the preRC would be
sufficient to block preRC assembly since each component is absolutely essential for
replication. However, no single control mechanism is perfect, and even limited rereplication
is potentially harmful in terms of maintaining a stable genome. For those reasons, ensuring
that little to no rereplication takes place requires the regulation of more than one preRC
component. These regulatory strategies include regulated protein degradation, Cdk-
dependent inhibitory phosphorylation, transcriptional control, and inhibition by direct
binding. This multifaceted approach to preRC inhibition is a characteristic of all eukaryotic
systems, but the details of the individual regulatory events vary across species, particularly
when comparing the budding and fission yeasts to multicellular eukaryotes. Nevertheless,
general strategies such as phosphorylation to induce protein degradation are broadly
conserved even when the species-specific protein targets of that phosphorylation vary.
3.3.1. Transcriptional control—Each of the metazoan preRC subunits is the product of
a gene under control of the E2F-Rb transcriptional program. The genes encoding preRC
proteins are suppressed by Rb-E2F-mediated repression in quiescence and derepressed in
late G1 as cells re-enter the cycle (28–31). At least some of these genes (cdc6, mcm2,-4 and
6) also display cell-cycle regulated fluctuations in mRNA abundance with peak expression
occurring in late G1 followed by down-regulation in S phase and G2 (30). Presumably the
phosphorylation of Rb (and the related p107 protein) in S phase and G2 contributes to the
Cook Page 3













down-regulation of those genes. However, because the MCM and Orc2-6 proteins are
relatively stable, they show minor if any cell cycle-dependent fluctuations even when their
mRNA levels rise and fall. On the other hand, the Cdt1, Cdc6, and Orc1 proteins are
unstable and degraded each cell cycle, so transcriptional control of these genes likely
contributes to controlling licensing competence during each cell cycle.
Extensive analyses of a wide variety of human cancers have revealed near-universal
deregulation of the E2F-Rb pathway. One consequence of loss of Rb-mediated repression is
the overproduction of preRC components, often to quite high levels (28, 29, 31, 32). This
overproduction has provided potentially useful markers of DNA replication competence in
clinical samples (33, 34). Moreover, the deregulated expression of preRC components –
sometimes by as much as 30-fold (31, 35) – could promote inappropriate licensing simply
by overwhelming the normal regulatory controls. Hyperaccumulation of preRC proteins in
transformed cells may induce rereplication and contribute to the genome instability
characteristic of cancer cells. In support of that idea, even moderate overproduction of Cdt1
are Cdc6 in cell lines is sufficient to promote carcinogenesis when implanted in mice (36,
37). Moreover, using DNA fiber analysis we have recently observed that the transformed
HeLa cell line continually produces DNA replication tracks consistent with rereplication at a
rate 3-times higher than an untransformed fibroblast cell line (38).
3.3.2. Cdk-dependent phosphorylation—A highly conserved feature of replication
licensing control is the inhibition of licensing once S phase Cdks become active. Since these
kinases trigger the firing of individual origins, coupling their activity to the cessation of
origin licensing effectively creates a clear transition from the licensing step to replication
initiation while simultaneously preventing origin relicensing. Inhibition of Cdk activity after
the G1/S transition can induce inappropriate MCM reloading onto chromatin (39, 40) and
subsequent rereplication (41–43), and Cdk suppression can further enhance rereplication
associated with other perturbations in licensing control (44). Furthermore, high levels of
Cdk2 during the licensing period block MCM loading onto Xenopus chromatin (45), and
ectopic Cyclin A/Cdk2 expression in human cells delays MCM chromatin loading (46).
Despite the clear role of Cdk-dependent phosphorylation in preventing rereplication, the
precise mechanism to explain this role remains undetermined in many cases. Every
component of the preRC (ORC, Cdc6, Cdt1, and MCM) is a target for Cdk-dependent
phosphorylation, but in many cases the phosphorylation sites and the molecular
consequences of those modifications are still largely unclear.
ORC associates with chromatin throughout the cell cycle, though there are indications that
the affinity of Xenopus ORC for chromatin may weaken during mitosis as consequence of
Cyclin A-dependent activity (47). Cdk-dependent phosphorylation of Drosophila (48) and
human (49) ORC subunits may be responsible for similar observations. Yeast Orc2 and
Orc6 are phosphorylated during S phase, and mutational alteration of the Cdk target sites
induced substantial rereplication in a yeast strain background where MCM and Cdc6 are
also altered to prevent Cdk dependent inhibition (50). The requirement for Orc2 and Orc6
mutational alteration indicates than those phosphorylation events block ORC function in
some as yet unknown way. It is not known if human Orc2 and Orc6 are phosphorylated in a
similar manner or if phosphorylation of human ORC subunits contributes to rereplication
inhibition. The coincident suppression of preRC assembly with the rise in Cdk activity
certainly creates the potential for a link between ORC phosphorylation and restricting ORC
chromatin association or function.
Human Cdc6 is phosphorylated by Cdk2 in association with Cyclin E (51) or Cyclin A (52,
53). This phosphorylation has at least two consequences: First, Cdc6 is protected from
ubiquitin-mediated degradation (see details below). Second, at least a fraction of the Cdc6
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molecules are exported from the nucleus to the cytoplasm. In stark contrast, Cdk-mediated
phosphorylation of yeast Cdc6 induces its ubiquitination and degradation. The Cdk binding
and phosphorylation sites of both yeast and human Cdc6 are found in their respective N-
terminal regions, but these domains are otherwise virtually unrelated which is consistent
with their divergent cell cycle regulation. In human cells at least a portion of the Cdc6
protein remains nuclear and chromatin bound throughout S phase (54, 55), raising the
question of just how important nuclear export is in restricting rereplication. On the other
hand in the nematode C. elegans, phosphorylation-induced Cdc6 export appears to play a
critical role in restricting rereplication (56). It may be that nuclear export of human Cdc6
could be equally important for preventing rereplication in some human cell types. The fact
that nearly all human replication studies are conducted in cultured fibroblasts or cancer cell
lines (mostly epithelial) means that our view of the relative contributions of different control
mechanisms in different cell types is still unfortunately narrow.
Cdk-mediated phosphorylation of human Cdt1 induces association of Cdt1 with the Skp2
ubiquitin ligase complex. As a result, Cdt1 is ubiquitinated and degraded. Cdt1
preferentially associates with cyclin A –containing complexes as opposed to cyclin E or
cyclin B complexes (57, 58), suggesting that its phosphorylation is primarily catalyzed by
cyclin A/Cdk2 from mid-S phase through G2. The down-regulation of Cdt1 levels by Skp2-
mediated poly-ubiquitination may not be the only consequence of Cdk-mediated
phosphorylation however. Cdt1 has affinity for DNA (at least in vitro (59), and
phosphorylation by Cdk2 diminishes this ability (57).
At least three subunits of the human MCM complex, Mcm2, Mcm3, and Mcm4, are
phosphorylated during S phase and G2, and these phosphorylations have been attributed to
Cdk activity (60, 61). Importantly, the hyperphosphorylated forms of these subunits are not
associated with chromatin, implying that phosphorylation inhibits MCM chromatin
association. In yeast, phosphorylation of at least one subunit of the MCM complex induces
its translocation from the nucleus to the cytoplasm (62, 63), but his mechanism does not
apply to cultured human cells (64, 65). It appears that the regulatory mechanism by
cytoplasmic accumulation was transferred to human (and nematode) Cdc6 instead. It is not
clear if phosphorylation of human MCMs blocks their ability to bind to other members of
the preRC during assembly, though such a mechanism is attractive. Interestingly, Mcm2 has
intrinsic histone-binding affinity, and it may be that phosphorylation influences that
interaction (66). Not all Cdk-mediated MCM phosphorylation is inhibitory however. Recent
identification of a Cdk1-specific site on Mcm3, Ser 112, demonstrated a positive role for
Cdk phosphorylation in assembly of the MCM heterohexameric complex in G2 and M
phases. The fact that Cdk activity can be both a positive and a negative factor in different
individual steps in the replication process creates significant challenges for interpreting the
precise outcome from changes in Cdk activity with particular regard to DNA replication.
Continued effort to map specific phosphorylation sites and determine the molecular
consequences of those modifications is clearly needed to distinguish activating and
inhibitory phosphorylation events.
3.3.3. Ubiquitin-mediated degradation—Active degradation plays a large role in
preventing inappropriate preRC assembly. Human Cdt1 is degraded in S phase by the
combined action of two ubiquitin ligases, Skp2 and Cul4 (67). (Yeast Cdt1 is not degraded
but rather exported from the nucleus to the cytoplasm along with MCM during S phase
(68).) Skp2 interaction with Cdt1 requires prior phosphorylation of Cdt1 by Cdk2 (69–71),
and ectopic Cyclin A/Cdk2 activity in G1 is sufficient to prematurely downregulate Cdt1
and delay MCM loading (46). Cul4-mediated ubiquitination of Cdt1 requires that Cdt1 be
associated with chromatin-bound Proliferating Cell Nuclear Antigen (PCNA) (72–74). Thus,
activation of Cdk2 at the G1/S transition promotes Skp2-mediated ubiquitination of Cdt1
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whereas loading of PCNA at active replication forks promotes Cul4-mediated ubiquitination
of Cdt1 on chromatin. These two ubiquitination pathways operate independently of each
other leading to significant destruction of Cdt1 in S phase cells. It is clear that destruction of
Cdt1 at the onset of S phase contributes to preventing rereplication because mutational
alterations that stabilize Cdt1 result in origin re-firing and accumulation of cells with greater
than 4C DNA content (67, 74). Several studies have shown that the human Orc1 subunit can
also be targeted for Skp2-mediated ubiquitination and degradation during S phase, and that
this ubiquitination involves prior phosphorylation by cyclin A/Cdk2 (reviewed in (75)).
Like Cdt1, Cdc6 is degraded in each cell cycle, but unlike Cdt1, Cdc6 is degraded in late
mitosis rather than during S phase. Cdc6 levels remain high and actually increase during S
phase and G2. Cdc6 is then degraded after ubiquitination by the Cdh1-associated form of
APC/C, APCCdh1. Mailand and Diffley discovered that the recruitment of Cdc6 to APC/C
by Cdh1 is blocked by Cdk-mediated phosphorylation of Cdc6. In late G1, the rise in cyclin
E/Cdk2 activity promotes Cdc6 phosphorylation rendering it resistant to APCCdh1 (51, 76).
Cdc6 phosphorylation in late G1 then provides a window of opportunity for Cdc6
accumulation and MCM loading before S phase when much of the Cdt1 is destroyed. APC/
C itself is inhibited during S phase and G2 by multiple mechanisms, one of which is
phosphorylation by Cdks (77, 78). APC/C inhibition allows Cdc6 to accumulate
significantly throughout S phase and G2, but without active Cdt1, MCM loading is blocked.
Cdc6 remains chromatin-bound in S phase and G2 (54, 79), and has been implicated in some
aspects of the G2/M checkpoint ((79–81) discussed below). The abundance of chromatin-
bound Cdc6 in S phase likely explains why aberrant accumulation of Cdt1 so potently
induces rereplication.
3.3.4. Geminin—Not all of the Cdt1 is degraded during S phase by Skp2 and Cul4-
mediated ubiquitination. The remaining Cdt1 is associated with geminin, a protein unique to
metazoan species that accumulates during S phase and G2. High levels of geminin prevent
licensing during S phase by blocking the association of Cdt1 with Cdc6 and the MCM
complex (59, 82). Surprisingly, lower levels of geminin are compatible with MCM loading
in X. laevis egg extracts, though it is not clear if geminin actively promotes licensing or if it
is recruited to facilitate subsequent preRC inhibition later in S phase (83). It is also not clear
if geminin plays a similar positive role in human cells. Geminin is regulated through poly-
ubiquitination by the anaphase promoting complex/cyclosome APC/C at the metaphase to
anaphase transition (84). Degradation of geminin in anaphase releases Cdt1 to permit a new
round of MCM loading beginning in telophase and throughout the subsequent G1 phase
(85). Geminin is sensitive to both the Cdc20 and Cdh1-activated APC complexes, whereas
Cdc6 is only sensitive to the Cdh1-activated form. Since the Cdc20 form appears before the
Cdh1 form, an additional brief window opens in telophase between the destruction of
geminin and the destruction of Cdc6 where MCM loading can occur (1).
Though geminin was originally named because it is expressed from two highly related
“twin” genes in X. laevis (84), the name turned out to be particularly appropriate. Geminin
has at least two distinct functions, one in preRC regulation and the other in transcription.
Specifically, geminin antagonizes both the expression and function of Hox transcription
factors (86, 87), and associates with Brg1 and Brm-containing SWI/SNF chromatin
remodeling complexes to regulate differentiation (88). Presumably, when geminin is
degraded each cell cycle, it becomes limiting for both replication inhibition and for
transcriptional control. The interplay between these two roles of geminin in replication and
transcription is still mysterious, but a common feature in both processes is chromatin and its
modifications.
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Loss of geminin by RNAi-mediated knockdown can induce significant rereplication by
releasing Cdt1 from inhibition and permitting inappropriate licensing during S phase and
G2. Similarly, Cdt1 overproduction, and to a lesser extent, Cdc6 overproduction, also
stimulate rereplication (89). Recent advances in understanding the molecular details of
MCM loading with purified yeast proteins suggest that the role of Cdt1 might best be
described as an MCM “escort” from the nucleoplasm to the ORC-Cdc6 complex on
chromatin. Once the MCM complex is delivered to ORC-Cdc6 for loading, Cdt1 is released,
but ORC, Cdc6 and (of course) MCM remain behind (16). In that regard, a very small
amount of free Cdt1 may be sufficient to facilitate MCM loading at multiple origins. This
pseudo-catalytic role of Cdt1 could explain why disruptions in Cdt1 regulation have by far
the greatest effects on rereplication. The potency of free Cdt1 in promoting rereplication
may also explain why the Cdt1-specific inhibitor, geminin, evolved in the rise of metazoan
species.
4. DNA DAMAGE AND REPLICATION STRESS
Clearly replication or segregation of damaged DNA would be deleterious. DNA damage
blocks cell cycle progression in order to create time for repair, or if the damage is too
extensive, induce apoptosis. A wide variety of genotoxic agents elicit this checkpoint
response including ultraviolet light (UV), ionizing radiation (IR), chemical crosslinkers, and
reactive compounds that generate bulky adducts at bases. Checkpoint-induced cell cycle
arrest is accomplished by inhibiting the activity of both Cdk2 and Cdk1 to simultaneously
block new origin firing and prevent premature entry into mitosis. Decades of research have
elucidated signaling pathways that are activated in response to DNA damage to both block
cell cycle progression and induce DNA repair activities (for reviews see (7–11, 90)), a few
key aspects as they relate to preRC regulation are briefly summarized below.
Two parallel signaling cascades are activated by DNA damage. Ionizing radiation and other
treatments that induce double-strand breaks induce the ATM kinase to phosphorylate and
activate the Chk2 kinase. ATM activation requires that the double-strand break be bound by
the MRN complex (Mre11/Rad50/Nbs1) as part of the damage recognition process (91). UV
irradiation and a wide variety of other DNA damaging agents activate the ATR kinase (in
association with its partner, ATRIP) to phosphorylate and activate the Chk1 kinase. In
addition, treatments that cause replication fork stalling, such as drugs that suppress
nucleotide pools (e.g. hydroxyurea) or inhibit DNA polymerase (e.g. aphidicolin) also
potently activate ATR and Chk1 although such treatments do not directly attack DNA.
Emerging evidence indicates that the generation of single-stranded DNA bound by RPA is a
common intermediate in these forms of damage and is a major contributor to ATR activation
(92, 93). ATR and ATM are primarily activated by different types of DNA damage, but
considerable crosstalk between the two pathways often results in both branches ultimately
responding to a single type of exogenous damage (94).
ATM and ATR, as well as Chk1 and Chk2, phosphorylate and stabilize the p53 transcription
factor by interfering with p53 polyubiquitination. p53 regulates a cohort of genes involved
in DNA repair, apoptosis and cell cycle progression as well as the Cdk inhibitor, p21, which
functions to prevent entry into S phase after damage (95). Independently of p53, Chk1 and
Chk2 phosphorylate the Cdc25 family of dual-specificity phosphatases to inhibit their
activity and/or promote their degradation, depending on which of the Cdc25 isoforms is
targeted. Cdc25 is responsible for removing inhibitory threonine and tyrosine
phosphorylations from both Cdk2 and Cdk1. The combined results of these interactions are
to block Cdk activity after DNA damage (Figure 2). In the absence of sufficient Cdk2
activity, GINS and Cdc45 are not recruited to any origins that remain unfired, thus blocking
replication initiation. Furthermore, the inhibition of cyclin B/Cdk1 by DNA damage
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prevents entry into mitosis. In addition to inhibiting Cdk-dependent Cdc45 loading at
origins, Cdk-independent inhibition of Cdc45 loading has also been suggested through
inhibition of Cdc7/Dbf4 protein kinase activity (96–98).
High levels of damage not only block replication initiation, but can also cause Chk1-
dependent inhibition of DNA chain elongation and premature termination of ongoing forks
(99, 100). A potential target for Chk1 in elongation is the tousled-like kinase, Tlk1. Tlk1
phosphorylates and activates Asf1, an essential chromatin assembly factor (101). Tlk1
activity normally peaks in S phase, but is strongly inhibited by DNA damage in a Chk1-
dependent manner, and Tlk1 can be phosphorylated by Chk1 in vitro (102, 103). DNA
synthesis and chromatin assembly are tightly coordinated, though the intricacies of that
coordination are not well understood. It may be that Tlk1 inhibition by Chk1 slows
replication fork progression by blocking chromatin assembly at replication forks. Activation
of ATR and Chk1 also protects stalled replication forks so that DNA synthesis can proceed
once conditions return to normal. The mechanism by which ATR and Chk1 prevent
replication fork collapse is incompletely understood, but could involve suppression of
homologous recombination (9) and direct regulation of replication fork components (90).
5. THE ATR-CHK1 PATHWAY IN UNPERTURBED CELL CYCLES
While some signaling components, such as ATM and Chk2, are only needed in cells
exposed to exogenous DNA damage (104), other components such as ATR and Chk1 are
essential even in the absence of DNA damage. Mice nullizygous for either ATR or Chk1 die
during very early embryonic development (105–107). Thus far, the role of the ATR/Chk1
pathway in unperturbed cell cycles appears to be highly related to its role in the DNA
damage response, namely the regulation of Cdk activity and control of DNA replication.
Since ATR-Chk1 pathway contributes to the regulation of Cdk2 and Cdk1 activity in normal
cell cycles, and since Cdk activity regulates licensing, the ATR-Chk1 pathway may have a
role in preRC control in the absence of damage.
In cultured cells, elimination of Chk1, ATR, or its essential partner ATRIP, leads to
premature mitosis before replication has completed (108, 109). This uncoupling of mitotic
entry with S phase progression is “mitotic catastrophe,” and is a lethal event. The ATR-
Chk1 pathway is required to block mitosis when replication forks are stalled by treatment
with hydroxyurea or aphidicolin. Niida et al. employed a knockout/knock-in approach to
directly demonstrate that mitosis is restrained by phosphorylation of Chk1 in unperturbed
cells indicating that at least one of the essential functions of Chk1 is to control the timing of
mitotic entry relative to the completion of replication (110). Chk1 also regulates Cdc25A
and Cdc25B stability in unperturbed cell cycles as well as after DNA damage (111, 112)
which may prevent premature activation of both Cdk2 and Cdk1. Moreover, the fact that
ATR and Chk1 are activated by slow or stalled replication forks, suggests that these kinases
could function in unperturbed cell cycles to stabilize forks at natural pause sites. Regions of
altered chromatin, DNA secondary structure, transcription machinery, and matrix
attachment sites are all likely to influence the ability of a replication fork to proceed. It may
be that in the absence of the ATR-Chk1 pathway, forks collapse much more frequently
during S phase leading to an inability to complete DNA replication and contributing to cell
death.
Recent investigations have indicated that ATR and Chk1 can restrain origin firing in normal
cell cycles as well as after DNA damage perhaps by controlling the ability of Cdc45 to load
at origins. Inhibition of ATR-Chk1 activity or depletion of Chk1 protein results in a shorter
distance between active origins, suggesting that origins that are normally dormant fire in the
absence of Chk1 (113–116). The ability of these dormant origins to fire during S phase
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requires that they were licensed in the preceding G1, and they may be important under
conditions where replication is slowed. Precisely how ATR-Chk1 is regulated to permit the
firing of these dormant origins under appropriate conditions and how that regulation differs
from the strong origin inhibition by ATR-Chk1 during a checkpoint response is still unclear.
Chk1-depleted cells have been reported to exhibit not only more origin firing but also slow
fork progression (99, 100). If Chk1 is responsible for the regulation of Asf1 phosphorylation
by Tlk1 to control chromatin assembly during a DNA damage response, then it may also
play that role in normal S phases. The interpretation of these findings is complicated by the
fact that Chk1 depletion also promotes replication stress and even frank DNA damage that
may be the result of stalled and collapsed forks (114). It is not clear if the effects of Chk1
depletion on replication dynamics reflects a direct role of Chk1 or if these effects are the
indirect consequence of fork collapse initiating a DNA damage response. The fact that the
loss of Chk1 induces DNA damage suggests that Chk1 both responds to DNA damage and
plays a role in preventing the damage in the first place.
Chk1 can be detected on chromatin, though the requirements for that chromatin association
are not yet known. Strikingly Chk1 chromatin binding is inhibited when Chk1 becomes
phosphorylated after DNA damage, raising the possibility that Chk1 release from chromatin
disseminates the checkpoint signal throughout the cell (110, 117). Could chromatin-binding
sequester Chk1 to allow late origin firing and normal S phase progression? Moreover, in
normal cell cycles Chk1 shifts its localization from the nucleus to the cytoplasm during late
S/G2 (118). It is becoming increasingly clear that the localization of Chk1 is an important
aspect of its role in regulating mitosis (119, 120); localization may be similarly important in
the control of origin firing. If one of the normal functions of Chk1 is to suppress origin
firing, and if that function requires nuclear Chk1, then relocalization of Chk1 to the
cytoplasm could permit the firing of any dormant origins that still remain in late S phase to
ensure completion of S phase.
6. MAINTAINING LICENSING CONTROL DURING CHECKPOINT
ACTIVATION
The inhibition of Cdk activity during a DNA damage response eliminates an important
mechanism to control replication licensing and prevent rereplication. Once Cdks are
inhibited by the checkpoint, phosphorylation of ORC, MCM, and Cdt1 would all be
suppressed promoting the inappropriate reloading of MCM complexes onto replicated
chromatin. When the DNA damage is extensive, cells are likely to initiate apoptosis, so
rereplication from these MCM complexes would likely be inconsequential in a cell that is
destined to die. The real danger may come from sub-lethal DNA damage – after S phase has
already begun - that is sufficient to activate the checkpoint and transiently inhibit Cdk
activity. During the period of low Cdk activity, MCM complexes may be loaded at origins
that have already fired. Once the damage is repaired and the checkpoint is quenched, Cdks
are reactivated, and such relicensed origins may fire a second time.
Despite the fact that geminin levels are unchanged after DNA damage (35, 69, 121), early
studies of Cdk inhibition suggested that the presence of geminin alone is not sufficient to
inhibit rereplication (41, 42). Indeed, pharmacological inhibition of Cdk activity in
nocodazole-arrested cells permits robust MCM re-association with chromatin in
prometaphase (39). On the other hand, in a recent study by Hochegger et al., Cdk inhibition
during periods of peak geminin expression were insufficient to permit MCM chromatin
loading, suggesting that (at least in the transformed avian cells tested) some cell cycle
periods are less dependent on Cdk regulation for preRC inhibition than others (43). Another
potentially sensitive time when Cdk activity may be particularly important is in early S
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phase when geminin levels are still rising, but perhaps insufficient to fully block MCM
loading. Furthermore, the relative levels of geminin and Cdt1 vary quite widely between
different tumor cell lines (122, 123), and may also vary between normal cells of different
tissue origin, though the relative abundance of geminin in different normal cell types has not
yet been explored. It seems likely that in cells that express lower levels of geminin, the
contribution of Cdk activity in restricting licensing is greater and vice versa.
Given the potential danger of relicensing previously replicated origins during a checkpoint
response, it would seem prudent to have additional means to inhibit rereplication that do not
rely on Cdk activity or geminin. Recent investigations have shown that components of the
preRC itself are targets for additional regulation in response to DNA damage. Most notable
among these are Cdt1 and Cdc6 which are ubiquitinated and degraded after damage.
6.1. Cdt1 ubiquitination and degradation
Cdt1 is eliminated from cells within minutes of a high dose of a DNA damaging agent such
as UV or IR. DNA damage-induced Cdt1 ubiquitination relies on one of the same ubiquitin
ligases that controls S phase degradation, Cul4 (121, 124) in association with DDB1 (DNA
Damage Binding protein 1) and a substrate adaptor, Cdt2 (125–128). Skp2-dependent
ubiquitination likely plays a minor role in DNA damage induced Cdt1 degradation, although
its contribution may be more prominent in some cell lines or cell types (67, 69). Strikingly,
in order for Cdt1 to be a target of Cul4/DDB1/Cdt2 it must associate with PCNA (72–74),
and both PCNA and Cul4/DDB1 are chromatin-associated not only during S phase, but also
during DNA repair (reviewed in (129, 130)). Furthermore, core proteasome components
have been reported to localize to chromatin after DNA damage in yeast (131) and possibly
in human cells as well (132). This convergence of factors prompted a model for the
regulation of Cdt1 ubiquitination in which PCNA chromatin localization at DNA repair sites
positions Cdt1 near an active DDB1/Cul4/Cdt2 ligase (129, 133, 134). In support of that
model, evidence for an interaction between X. laevis Cdt1 and PCNA could only be detected
on chromatin (74). On the other hand human Cdt1 can interact with soluble PCNA (67, 72).
It will be important to sort out exactly where Cdt1 ubiquitination occurs in order to
determine the requirements for that event, particularly in human cells.
Given that Cul4 is brought to Cdt1/PCNA by the direct association of Cdt1 with DDB1,
which as its name implies can bind directly to damaged DNA, Cdt1 ubiquitination by Cul4
likely occurs independently of the activation of the damage checkpoint pathway. Chromatin
localization may not be the only regulatory event that governs Cdt1 after DNA damage
however. In at least one study, caffeine treatment which can override the DNA damage
checkpoint or treatment with the Chk1 kinase inhibitor UCN01 blocked the UV induced -
but not the IR-induced - degradation of Cdt1 (69). Another study confirmed that IR-induced
degradation is independent of checkpoint kinases using both caffeine and RNAi-mediated
knockdown of checkpoint kinases, but did not test UV-induced degradation (121). It is thus
possible that Chk1 contributes to the Cdt1-PCNA interaction on chromatin or to the
activation of Cul4/DDB1/Cdt2 after UV irradiation, though such regulation has not yet been
reported. As mentioned earlier, geminin levels do not change in response to DNA damage.
What is the fate of the Cdt1-geminin complex in this context? Is geminin brought with Cdt1
to chromatin, but not ubiquitinated? Does the interaction of Cdt1 with PCNA or Cdt1
ubiquitination release geminin into the nucleoplasm to inhibit additional Cdt1 molecules? In
other words, is the actual target of Cul4/DDB1/Cdt2 free Cdt1 or geminin-bound Cdt1 (or
both)? The answers to such questions are relevant to our complete understanding of how
Cdt1 regulation is achieved in order to prevent rereplication.
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6.2. Cdc6 ubiquitination and degradation
Like Cdt1, Cdc6 is ubiquitinated and degraded after all forms of DNA damage. Also like
Cdt1, a ubiquitin E3 ligase that controls the cell cycle-dependent degradation of Cdc6 plays
a role in damage-induced ubiquitination, though not exclusively. As outlined above, Cdc6 is
ubiquitinated during anaphase by APCCdh1. Importantly the interaction of Cdc6 with Cdh1
is inhibited by Cdk-dependent phosphorylation of Cdc6. This phosphorylation-induced
stabilization of Cdc6 allows Cdc6 to accumulate during G1 despite the presence of active
APCCdh1. A mechanism to stimulate Cdc6 ubiquitination by APCCdh1 after DNA damage
which relies on the dephosphorylation of Cdc6 after ionizing radiation and the subsequent
acquisition of APCCdh1 sensitivity was explored by Duursma and Agami (76). In that study
Cdc6 degradation after ionizing radiation required the induction of the p21 Cdk inhibitor by
p53 in order to promote Cdc6 dephosphorylation. On the other hand, Blanchard et al. found
that DNA damage induced p53-independent ubiquitination of Cdc6 (135). It thus appears
that Cdc6 can be degraded by both APC/C-dependent and APC/C-independent pathways.
A clue to how Cdc6 might be targeted for degradation by a Cdk and APC-independent
mechanism came from the discovery of an interaction between Cdc6 and the E3 ligase,
Huwe1. Huwe1 is a member of the HECT family of E3 ligases that includes E6-AP. Huwe1
has been implicated in the ubiquitination of a number of other factors involved in both cell
growth and cell death control, including p53, c-myc, core histones, and Mcl-1. (These
investigations have each given the E3 ligase a different name: ARF-BP1, HectH9, Lasu1,
and Mule (136–141).) Huwe1 ubiquitinates Cdc6 in vitro, and when Huwe1 expression is
suppressed, Cdc6 is significantly stabilized after DNA damage (35). Important questions
about the regulation of the Huwe1-Cdc6 interaction remain to be addressed. Is Huwe1
activity regulated by the DNA damage checkpoint? Huwe1 protein levels are constant
throughout the cell cycle and do not change upon DNA damage. Moreover, DNA damage
prevents Huwe1 from ubiquitinating p53, but promotes ubiquitination of Mcl-1, suggesting
that the absolute enzymatic activity of Huwe1 is not the target of regulation. Nevertheless, a
recent proteome-scale analysis of protein phosphorylation in response to DNA damage
identified both Huwe1 and two subunits of ORC as likely substrates of ATM and/or ATR by
virtue of their induced phosphorylation on the ATM and ATR consensus sequence S/TQ
(142). Phosphorylation of Huwe1 may affect its protein-protein interactions in ways that
alter substrate specificity, localization, or interaction with potential activators or inhibitors,
but the functional consequences of that phosphorylation have yet to be explored.
Another possibility is that the Huwe1 substrates themselves are the primary targets of
regulation. In support of that model, we found that Cdc6 is released from chromatin after
DNA damage (35). Since Huwe1 is a soluble nucleoprotein, movement of Cdc6 from the
chromatin to the nucleoplasm could promote ubiquitination by Huwe1. Precisely how Cdc6
chromatin binding is inhibited by DNA damage is not yet clear. Cdc6 association with
chromatin requires interaction with ORC, so an attractive explanation is that
phosphorylation of ORC by ATM or ATR inhibits Cdc6 binding and blocks further preRC
assembly. Furthermore, the fact that ORC is phosphorylated by a checkpoint kinase raises
the possibility that the kinase could be brought to origins by an ORC-ATM/ATR interaction
in order to carry out that phosphorylation. The recruitment of a checkpoint kinase to origins
may promote the phosphorylation of additional preRC components, though that idea has not
yet been addressed.
6.3. MCM phosphorylation
Another potential mechanism to block rereplication after DNA damage involves the
phosphorylation of multiple MCM subunits by the ATM and ATR kinases. Cortez et al.
detected Mcm3 in a biochemical screen for proteins phosphorylated on the ATM/ATR
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consensus sequence S/TQ (143). These investigators went on to demonstrate that Mcm2 is
also an ATR substrate and furthermore, that Mcm7 associates with the ATR binding partner
ATRIP. Similarly, X. laevis ATM and ATR phosphorylate Mcm2 in egg extracts (144), and
Mcm4 is heavily phosphorylated after UV irradiation or replication inhibition (145). Though
phosphorylation of both Mcm2 and Mcm3 after UV and IR-induced damage was robust, the
physiological consequences of these events regarding preRC assembly remains to be
determined. Unlike Cdt1 and Cdc6, DNA damage did not induce the degradation of any of
the MCM subunits, nor did it detectably alter their chromatin association shortly after
damage. It may be that phosphorylation of MCM proteins inhibits the DNA helicase activity
of the complex rather than inhibiting its loading onto chromatin (145). Alternatively,
phosphorylation of the MCM complex by ATR may contribute to maintaining MCM at a
stalled fork to prevent replication fork collapse. It is not yet known if ATR targets only the
MCM complexes that are actively participating at replication forks, or if origin-bound MCM
or soluble MCM are also substrates. A recent report by Trenz et al. suggested that the
binding of a polo-like kinase, Plx1, to Xenopus chromatin is required for full replication in
the presence of low amounts of replication inhibitors such as aphidicolin. The precise
stimulatory effects of Plx1 binding on replication activity are not yet known, but its induced
association with chromatin required the ATR-dependent phosphorylation of Mcm2 (146).
7. MUTUAL REGULATION OF ORIGIN LICENSING AND THE DNA DAMAGE
RESPONSE
PreRC components are not only regulated in response to DNA damage, but they can also
induce a DNA damage response. In that regard, preRCs are both “downstream” targets of
the DNA damage checkpoint and “upstream” inducers of the checkpoint. This mechanism of
checkpoint activation is largely indirect, but reports of interactions among replication factors
and checkpoint proteins suggest that preRC components could also have direct effects on the
activity of checkpoint activities.
7.1. Rereplication causes DNA damage
Re-replicated DNA ultimately causes DNA damage, including, but not necessarily limited
to, double-strand breaks. Manipulations that permit MCM loading in S phase or G2 induce
phosphorylation of Chk1, Chk2, and p53 (147–150). Chromosome fragmentation as a
consequence of rereplication has also been directly detected in S. cerevisiae (151) and in X.
laevis rereplication assays (148). How exactly does re-firing of an origin cause DNA
damage when normal replication does not? Not all origins are equally sensitive to
rereplication (89, 147, 151, 152), so limited MCM re-loading at only a subset of origins
means that the additional replication forks are likely to be widely spaced from one another.
Under such circumstances forks will not always meet their neighbors to converge, and the
outcome is eventual fork collapse leading to chromosome fragmentation. It is also possible
that the presence of multiple forks on the same chromosomal segment places unusual
torsional strain on the DNA itself leading to fragmentation. Davidson et al. proposed a
straightforward model to explain the appearance of short DNA fragments under conditions
of massive rereplication. They suggested that the second forks eventually catch up with the
first forks, perhaps as a result of natural pause sites that slow the first fork. MCM helicase
activity from the second pair of forks could release a double-stranded DNA fragment
containing the re-fired origin (148).
Is rereplication the only way that preRC components interact with the DNA damage
checkpoint pathway? Perhaps not. In a surprising study, Tatsumi et al. observed molecular
markers of ATR and ATM pathway activation when Cdt1 was overproduced in quiescent
cells. These contact-inhibited and serum-deprived cells stained positive for phosphorylated
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ATM without detectable DNA synthesis. The mechanism to account for this observation has
not yet been determined, but the authors suggested that the DNA binding ability of Cdt1
may directly perturb chromatin when Cdt1 is overproduced. Another possibility could be
through physical association between Cdt1 and checkpoint factors, either directly or via
MCM complexes which are known to interact with both Cdt1(59, 82) and with the ATM and
ATR kinases (143).
Exciting possibilities also exist for other direct interactions between preRC components and
checkpoint signaling proteins. An early report that overproduction of Cdc6 in G2 cells
caused a Chk1-dependent block to mitosis, could indicate a direct role for Cdc6 in Chk1
activation, but might also be explained if Cdc6 induced rereplication which in turn, activated
Chk1 (80). More direct evidence for a functional interaction between Cdc6 and Chk1 comes
from the work of Oehlmann et al. in which X. laevis Cdc6 was shown to be required for
Chk1 activation by DNA damage independently of its role in MCM loading (79). After S
phase entry, Cdc6-depleted extracts showed a defect in Chk1 activation even though MCM
loading had already been accomplished in the preceding G1. Moreover, ORC-depleted
(Cdc6-containing) extracts were competent for Chk1 activation despite the fact that ORC is
required for Cdc6 chromatin binding (79). In human cells, depletion of Cdc6 after the G1/S
transition using siRNA induced a similar defect in Chk1 activation as well as an S phase
progression defect (81). These studies fall just short of demonstrating a direct association
between Cdc6 and Chk1, but they do suggest that Cdc6 has checkpoint functions that cannot
be easily explained solely through its role in MCM loading in G1. Perhaps this novel
function is the reason why Cdc6 is so abundant in G2 cells instead of being degraded in S
phase like Cdt1.
7.2. The DNA damage response restricts rereplication
Once rereplication has induced sufficient DNA damage to trigger activation of the ATM and
ATR pathways, further rereplication should be suppressed by the checkpoint-dependent
inhibition of new origin firing. In the same way that exogenous DNA damage blocks origin
firing, rereplication-induced damage activates p53 and suppresses Cdk activity (147, 149).
In support of this feedback inhibition of rereplication, Cdt1 overproduction induces
rereplication much more readily in cells deficient for ATR or p53 than in cells with normal
ATR and p53 (89, 153, 154). These assays for rereplication all rely on relatively insensitive
methods to detect rereplicated DNA – either by flow cytometry or density gradient
centrifugation of total cellular DNA. A significant portion of the genome must be
rereplicated in order to be detected. For this reason it is not yet clear, if the role of the ATR
pathway in restricting rereplication primarily impacts origin licensing, origin firing, fork
elongation, fork stabilization, or delaying mitosis since all of those events are required to
produce enough rereplicated genomic DNA to be detected.
As outlined above (sections 6.1 and 6.2), DNA damage induces the ubiquitination and
degradation of both Cdt1 and Cdc6. If rereplication induces DNA damage sufficient to
activate the ATR and ATM checkpoint pathways, then might that DNA damage also induce
Cdt1 and Cdc6 degradation? The first hint that this mechanism may be operating in
rereplicating cells came from observations that geminin-depleted human or Drosophila cells
also have very low levels of Cdt1 (39, 150). We have extended these observations to
demonstrate that Cdc6 is also degraded when rereplication is induced (155). Interestingly,
the rereplicated genomic DNA that is observed after geminin depletion could only
accumulate in the short time period between geminin depletion and the subsequent
degradation of Cdt1 and Cdc6. Stabilization of either Cdt1 or Cdc6 by disruption of the
ubiquitin ligases that target them during a DNA damage response, Cul4 and Huwe1
respectively, allowed for even more rereplication than could be observed from geminin
depletion alone. We argue that rereplication once it begins is then limited by the
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combination of origin licensing inhibition (destruction of Cdc6 and Cdt1) and checkpoint
activation (Cdk inhibition, MCM and ORC phosphorylation, etc.) that blocks origin firing
and limits fork progression. Interestingly, Chk1 depletion or inhibition can be sufficient to
induce DNA damage from replication fork collapse (114). It is not yet known however if
this DNA damage is also sufficient to induce Cdc6 and Cdt1 degradation.
The rereplication induced by geminin depletion or by Cdt1 or Cdc6 overproduction is
typically irregular and uneven. Individual cells have widely varying amounts of over-
replicated DNA as though only a subset of origins have re-fired. Indeed when the over-
replicated DNA was purified and hybridized to human metaphase chromosomes, large
regions of the genome were not detectably re-replicated at all. Similarly, induction of
rereplication in budding yeast results in uneven origin firing with some origins apparently
firing more than one extra time and others not at all (50, 151, 152). What determines the
difference between origins that re-replicate and origins that don’t? Differential chromatin
modification is one attractive explanation, but it may not fully account for the observed
differences. A satisfactory model would need to accommodate mechanisms that still permit
MCM loading at rereplication-resistant origins in a normal G1. The overall role of
chromatin in preRC assembly and replication initiation is another important question that
remains to be answered. The relative crudeness of the available rereplication assays can be
attributed in part to our lack of knowledge about the location and characteristics of human
origins themselves. Progress in mapping and analyzing human origins will allow better
rereplication assays based on detection of specific sequences either by PCR or by single
fiber probing.
8. CONCLUDING REMARKS
For many years, the pathways that halt cell cycle progression in response to exogenous DNA
damage were studied as distinct branches of cell cycle control. Signaling molecules in these
pathways have often been described as waiting in an inactive state under normal growth
conditions, “watching” for attack on the DNA or for replication forks to stall. Upon signal
activation, a cascade of events would then be put in place to prevent new replication
initiation events and to block mitosis while simultaneously activating appropriate repair
measures. Once such repairs were completed, the signaling molecules presumably returned
to their inert states until the next emergency response. In this model, checkpoint factors do
not influence or interact with the replication process in the absence of DNA damage.
The view that is currently emerging suggests that the checkpoint proteins are constantly
regulating mitotic entry and replication activity in order to prevent cell death and DNA
damage. Furthermore, replication itself regulates checkpoint activity at multiple levels. This
more integrated relationship between the checkpoint and the processes it monitors provides
opportunities for mutual regulation and information sharing between the systems. Some of
those connections may be indirectly carried by DNA itself in the form of damage, and some
may involve direct protein-protein interactions such as among ORC, MCM and ATM /ATR.
Future developments will undoubtedly shed light on how these interactions coordinately
ensure genome integrity.
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Replication licensing is restricted to G1. Pre-replication complexes (preRC) are assembled
at origins during G1 by the loading of MCM complexes by ORC, Cdc6, and Cdt1. Origin
firing requires loading of Cdc45 and GINS (not shown) which is induced by the action of
Cdk2 and Cdc7 in S phase. After the G1/S transition Cdk2 (and Cdk1) plus geminin
inhibition of Cdt1 block any new MCM chromatin loading in order to prevent rereplication.
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DNA damage induces intracellular signaling cascades that block DNA replication and cell
cycle progression. Two parallel branches, the ATR-Chk1 and ATM-Chk2 pathways are
activated by different forms of damage. Cdk activity is inhibited by degradation/inhibition of
Cdc25 phosphatases and by the p53-dependent induction of the p21 Cdk inhibitor. Cdk-
independent events also block origin firing through inhibition of Cdk and Cdc7 kinase
activity. The Tlk1 kinase which promotes Asf1-dependent chromatin assembly is also
inactivated in response to DNA damage.
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DNA damage regulates both origin licensing and origin firing. DNA damage induces the
phosphorylation of MCM and ORC subunits, while stimulating the ubiquitination and
degradation of Cdt1 and Cdc6. The DNA damage-activated checkpoint also blocks Cdc45
loading at origins to prevent replication initiation.
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